Skip to content

Study · Measured the body's own peptide · 2025

3 results

Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans.

Galbiati F, Plessow F, Plummer L, Campbell MB, Nazarloo S, Carter CS, Carroll RS, Kim HK, Pereira SA, Paulis D, Davis JM, Miller KK and 4 more

Show all authors

Kaiser UB, Seminara SB, Aulinas A, Lawson EA

European journal of endocrinology1 Mar 2025Cited by 7 (Europe PMC)

PMID39965102 (opens in a new tab)PMCIDPMC11886556 (opens in a new tab)DOI10.1093/ejendo/lvaf001 (opens in a new tab)PepBankPUB-39965102
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelNon-randomized trialEfficacy outcome

    In 12 healthy adults, intravenous kisspeptin-112-121 increased serum oxytocin by 18.8% from baseline 10 minutes after administration.

    In plain wordsIn healthy adults, a kisspeptin injection raised the body's own oxytocin level by 18.8% after 10 minutes.

    Peptide
    Oxytocin
    Outcome
    IncreaseSerum oxytocin 10 min after intravenous kisspeptin
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Measurements

    Serum OXT increase at 10 min
    18.8%
    all participants

    Source sentences

    Summary
    Ten minutes after KP, OXT increased by 18.8% from baseline (FDR-P = .004) with a greater increase in males than females (31.9% vs 5.7%, respectively, FDR-P = .004).
    2 context sentences
    Summary · context
    Kisspeptin-112-121 (KP analog, 0.24 nmol/kg bolus) was administered to 12 healthy adults (50% female).
    Summary · context
    Serum OXT was measured before and 10, 20, 40, and 60 min after KP administration.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelNon-randomized trialEfficacy outcome

    In healthy adults, the kisspeptin-induced rise in serum oxytocin at 10 minutes was greater in males than in females (31.9% vs 5.7%).

    In plain wordsIn healthy adults, kisspeptin raised the body's own oxytocin more in men (31.9%) than in women (5.7%).

    Peptide
    Oxytocin
    Outcome
    MixedSex difference in serum oxytocin rise after kisspeptin
    Study

    n = 12

    Comparator
    Females versus males
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Measurements

    Serum OXT increase at 10 min
    31.9%
    males
    Serum OXT increase at 10 min
    5.7%
    females

    Source sentences

    Summary
    Ten minutes after KP, OXT increased by 18.8% from baseline (FDR-P = .004) with a greater increase in males than females (31.9% vs 5.7%, respectively, FDR-P = .004).
    2 context sentences
    Summary · context
    Kisspeptin-112-121 (KP analog, 0.24 nmol/kg bolus) was administered to 12 healthy adults (50% female).
    Summary · context
    Serum OXT was measured before and 10, 20, 40, and 60 min after KP administration.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelNon-randomized trialOther

    In 12 healthy adults, baseline serum oxytocin levels did not differ significantly between males and females.

    In plain wordsIn healthy adults, the body's own oxytocin level before kisspeptin was not clearly different between men and women.

    Peptide
    Oxytocin
    Outcome
    No significant changeBaseline serum oxytocin by sex
    Study

    n = 12

    Comparator
    Females versus males
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Source sentences

    Summary
    Males and females did not differ significantly in age, BMI, or baseline OXT levels.
    2 context sentences
    Summary · context
    Kisspeptin-112-121 (KP analog, 0.24 nmol/kg bolus) was administered to 12 healthy adults (50% female).
    Summary · context
    Serum OXT was measured before and 10, 20, 40, and 60 min after KP administration.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT00914823

Kisspeptin Administration in the Adult

Massachusetts General Hospitaln = 25623 Jun 2009 to 22 Oct 2021

Hypogonadotropic Hypogonadism · Kallmann Syndrome · GnRH Deficiency · PCOS · Polycystic Ovarian Syndrome · Hyperprolactinemia

Trial pageClinicalTrials.govUpdated 31 Jul 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:04 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.